share_log

神州细胞(688520.SH):14价HPV疫苗受试者已完成第三针接种,现正处在随访阶段

Shenzhou Cell (688520.SH): The subjects of the 14-valent HPV vaccine have completed the third dose, and are currently in the follow-up stage.

Gelonghui Finance ·  Nov 15, 2024 15:58

Gelonghui November 15th | Shenzhou Cell (688520.SH) Investor Relations Activity Record Form shows that the 14-valent HPV vaccine recipients have completed the third dose, are currently in the follow-up stage, and related research and data analysis are voluntary disclosure information by the company. The company will disclose information in accordance with laws and regulations based on business progress.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment